Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia to Evaluate the Benefit of Venetoclax (GDC-0199/ABT-199) Plus Rituximab Compared With Bendamustine Plus Rituximab

Trial Profile

A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia to Evaluate the Benefit of Venetoclax (GDC-0199/ABT-199) Plus Rituximab Compared With Bendamustine Plus Rituximab

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Venetoclax (Primary) ; Bendamustine; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms MURANO
  • Sponsors AbbVie; Genentech; Roche
  • Most Recent Events

    • 12 Dec 2023 Results (data cutoff date: 5 Aug 2022) of final analysis assessing response rates to follow-up therapy with Ven-based regimens, or Bruton tyrosine kinase inhibitor (BTKi) therapy, as well as time to the second PFS events presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 15 Jun 2023 Results of final analyses with 7 years median follow-up and Retreatment Substudy Analysis of Venetoclax- Rituximab (Venr)-Treated Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia presented at the 28th Congress of the European Haematology Association
    • 09 Jun 2023 According to an AbbVie media release, final seven-year follow-up data from this study were presented at the European Hematology Association (EHA) Annual Congress.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top